Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non‑Small Cell Lung Cancer
Zipalertinib added to platinum‑based chemotherapy significantly improved progression‑free survival versus chemotherapy alone in first‑line treatment of EGFR exon 20 insertion metastatic NSCLC, as shown by the interim analysis of the Phase 3 REZILIENT3 trial.
This press release reports that the interim analysis of the Phase 3 REZILIENT3 study found that adding zipalertinib to platinum‑based chemotherapy improved progression‑free survival in first‑line EGFR exon 20 insertion NSCLC versus chemotherapy alone. The trial met its primary endpoint, supporting zipalertinib’s potential as a new treatment option.
These data represent a significant advance for patients with EGFR exon 20 insertion NSCLC, a subgroup with limited therapeutic options and poorer outcomes, addressing an unmet medical need.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT